AMEX · Biotechnology

Channel Therapeutics Corporation (CHRO) Stock

$1.35 +7.14% AMEX: CHRO Healthcare

Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1.7 sodium ion-channel, in addition to other related receptors within the broader NaV family.

Valuation

MetricValue
Price$1.35
Market Cap$8.90M
P/E Ratio-0.05
P/B Ratio0.13
P/S Ratio0.32
EPS (TTM)$-23.04
52-Week High$54.29
52-Week Low$1.23
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-164.11%
ROA-35.49%
ROCE-18.50%
Gross Margin-0.70%
Operating Margin-80.39%
Net Margin-186.23%
Debt/Equity0.74
Current Ratio2.79

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$17.0M
Operating Profit$-1.0M$-2.0M$-7.0M$-8.0M$0
Net Profit$-1.0M$-2.0M$-7.0M$-8.0M$-43.0M
EPS$-0.10$-0.43$-1.28$-1.43$-23.04
Op Margin————0.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$0$0$1.0M$130.0M
Total Liabilities$4.0M$4.0M$7.0M$4.0M$92.0M
Cash$0$0$0$1.0M$18.0M
Borrowings$1.0M$1.0M$1.0M$2.0M$34.0M

Latest News

Adeia Picks a Fight, and Investors Pick the Exit Trefis · Jul 3, 2026 ChronoScale (CHRN) Stock Valuation After Sharp 1 Year Surge And Rich P/S Multiple Simply Wall St. · Jun 13, 2026 Top Midday Gainers MT Newswires · Jun 4, 2026 ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy GlobeNewswire · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-2.0M$-1.0M$-6.0M$-23.0M
Investing Cash Flow$0$0$0$0$-5.0M
Financing Cash Flow$2.0M$1.0M$0$0$45.0M
Net Cash Flow$0$0$0$0$18.0M
Free Cash Flow$-2.0M$-2.0M$-1.0M$-6.0M$-23.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.07
FCF Yield-397.30%
Quick Ratio1.86
Interest Coverage15.93
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APGNApexigen, Inc. $0.39 +8.48% -0.24 $9.57M 0.00%
BIORBiora Therapeutics, Inc. $0.22 +0.00% 0.00 $994994 0.00%
CRVO $2.56 -3.76% -1.09 $23.70M 0.00%
CSCICOSCIENS Biopharma Inc. $2.72 +0.00% -0.35 $8.57M 0.00%
IMVIFIMV Inc. $0.00 — -0.18 $23423 0.00%

About Channel Therapeutics Corporation

Channel Therapeutics Corporation operates as a clinical-stage biotechnology company, committed to the entire process of identifying, advancing, and bringing to market novel therapies aimed at reducing pain. Its research strategy centers on precisely inhibiting the NaV1.7 sodium ion-channel, in addition to other related receptors within the broader NaV family. The firm's flagship investigational drug, CC8464, is currently undergoing Phase 2a clinical evaluation. This compound is being explored for its potential efficacy in treating erythromelalgia and diverse forms of neuropathic pain. Founded in 2002, this New Jersey-based entity maintains its corporate headquarters in Freehold.

Channel Therapeutics Corporation is headquartered in US.

Channel Therapeutics Corporation (CHRO) stock trades at $1.35 with a market capitalization of $8.90M. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of 0.13, price-to-sales of 0.32. Over the past 52 weeks the stock has ranged between $1.23 and $54.29, and currently trades 97.5% below its 52-week high.

On profitability, Channel Therapeutics Corporation generates a return on equity (ROE) of -164.11%, return on capital employed of -18.50%, an operating margin of -80.39%, a net profit margin of -186.23%.

Official website: channeltherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides